News Sentiment

PTCT sentiment intelligence

PTC Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 78.59 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend active

-7.4% over one week, -0.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Is PTC Therapeutics (PTCT) Cheap On Fast Track News For PTC518?

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -7.4% Price reacting lower
Trend fit Trend active -0.5% over four weeks
Fair value 65.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 37
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
Market source 9
simplywall.st 5
Investing.com 5
Quartr 4
Seeking Alpha 3
Simply Wall Street 2
Investing.com Nigeria 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 18
Analyst action 3
Balance sheet 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-57 of 57
Investing.com Direct company coverage

PTC Therapeutics’ Mark Boulding, exec VP, sells $432,117 in stock

Mark Elliott Boulding, Executive VP and CLO at PTC Therapeutics, Inc., sold 5,079 shares of common stock for $432,117 on July 6, 2026, under a pre-arranged trading plan. Concurrently, he acquired 5,079 shares by exercising stock options for $220,242, increasing his direct holding

Tone
Positive 65/100
Event
Market update
Published
08 Jul 2026 22:10
Source
Investing.com
Investing.com Direct company coverage

Ptc therapeutics tech ops chief sells $4.1m in common stock

PTC Therapeutics' Chief Technical Operations Officer, Neil Gregory Almstead, sold approximately $4.1 million in common stock and acquired $1.8 million worth of stock on July 6 and 7, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. The sales o

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 22:10
Source
Investing.com
Stock Titan Direct company coverage

PTC Therapeutics (PTCT) CLO sells shares under Rule 10b5-1 plan

Mark Elliott Boulding, Executive Vice President and CLO of PTC Therapeutics (PTCT), reported selling 5,079 shares in open-market transactions and exercising options to acquire 5,039 shares on July 6, 2026. The sales were conducted under a Rule 10b5-1 trading plan adopted in Septe

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 21:10
Source
Stock Titan
Stock Titan Direct company coverage

PTC Therapeutics (PTCT) officer sells shares after exercising options

PTC Therapeutics' Chief Technical Operations Officer, Neil Gregory Almstead, sold 46,774 shares of common stock after exercising options. These transactions, executed on July 6-7, 2026, were performed under a pre-set Rule 10b5-1 trading plan. Almstead exercised options at prices

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 21:10
Source
Stock Titan